Inactive

This is a Notice of Intent to award, not a request for Quotation. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on a... This is a Notice of Intent to award, not a request for Quotation. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Genscript USA Incorporated for Custom Gene Synthesis. The goal of this project is to clone potent human monoclonal antibodies against Plasmodium falciparum blood?stage malaria parasites from Malian donors that become naturally infected with malaria in the field. This project is being conducted in collaboration with Dr. Peter Crompton, whose lab maintains an ongoing study site in Kalifabougou, Mali and is providing the PBMCs for this project. All monoclonal antibodies will be screened for in vitro inhibition of malaria parasites and the most protective will be selected for extensive structural characterization and in vivo protection studies in non?human primates. GenScript focuses exclusively on early drug discovery and development services, it offers molecular biology services ranging from gene synthesis and custom cloning, to advanced genetic engineering and mutant libraries. With in?house oligo synthesis capability and well?equipped molecular biology laboratory, this company provides reliable and flexible molecular biology service solutions that cover almost all aspects in discovery research. This company also stores synthesized plasmids that we ordered before so that we can conveniently clone genes needed for our previous DNA plasmids. This request will include DNA synthesis, subcloning, and mutagenesis. This service needs to also provide VectorArk/CloneArk System for NIH to archive, share and reuse their vectors and archived clones. The results from these services will be used at NIH for continued malaria studies within the Vaccine Research Center in Bethesda, MD The Place of performance NIH, VACCINE RESEARCH CENTER 40 CONVENT DR BETHESDA, MD 20892 The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106?1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR QUOTES. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI?RML?C?2034349 to Diana Rohlman at diana.rohlman@nih.gov by 9:00 AM Mountain Standard Time, August 3, 2020. All compatibility responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.